Reasner CA - Search Results

1

Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.

Reasner CA. Reasner CA. J Cardiovasc Pharmacol. 2008 Aug;52(2):136-44. doi: 10.1097/FJC.0b013e31817ffe5a. J Cardiovasc Pharmacol. 2008. PMID: 18670366 Review.

2

The Diabetes Control and Complications Trial Study: implications for the diabetic foot.

DeFronzo RA, Reasner C. DeFronzo RA, et al. J Foot Ankle Surg. 1994 Nov-Dec;33(6):551-6. J Foot Ankle Surg. 1994. PMID: 7894400 Review.

3

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ. Reasner C, et al. Diabetes Obes Metab. 2011 Jul;13(7):644-52. doi: 10.1111/j.1463-1326.2011.01390.x. Diabetes Obes Metab. 2011. PMID: 21410627 Clinical Trial.

4

First approved inhaled insulin therapy for diabetes mellitus.

Jani R, Triplitt C, Reasner C, Defronzo RA. Jani R, et al. Expert Opin Drug Deliv. 2007 Jan;4(1):63-76. doi: 10.1517/17425247.4.1.63. Expert Opin Drug Deliv. 2007. PMID: 17184163 Review.

5

Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.

Rosenson RS, Reasner CA. Rosenson RS, et al. Among authors: reasner ca. Curr Opin Cardiol. 2004 Sep;19(5):480-7. doi: 10.1097/01.hco.0000133111.66486.c6. Curr Opin Cardiol. 2004. PMID: 15316457 Review.

6

Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus.

Reasner CA. Reasner CA. Curr Atheroscler Rep. 2006 Jul;8(4):261-2. doi: 10.1007/s11883-006-0001-4. Curr Atheroscler Rep. 2006. PMID: 16822390 No abstract available.

7

Where thiazolidinediones will fit.

Reasner CA. Reasner CA. Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S30-5. doi: 10.1002/dmrr.250. Diabetes Metab Res Rev. 2002. PMID: 11921436 Review.

8

What is the most effective strategy for managing diabetic dyslipidaemia?

Reasner CA. Reasner CA. Atheroscler Suppl. 2005 Sep;6(3):21-7. doi: 10.1016/j.atherosclerosissup.2005.06.005. Atheroscler Suppl. 2005. PMID: 16054442 Review.

9

Promising new approaches.

Reasner CA 2nd. Reasner CA 2nd. Diabetes Obes Metab. 1999 May;1 Suppl 1:S41-8. Diabetes Obes Metab. 1999. PMID: 11220287 Review.

10

Diabetic nephropathy: pathogenetic basis for treatment.

Reasner CA 2nd, DeFronzo R. Reasner CA 2nd, et al. Contemp Intern Med. 1994 Oct;6(10):30-2, 35-40. Contemp Intern Med. 1994. PMID: 10150289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results